SCHEMBL5164037

SCHEMBL5164037

Nc1nc(-c2cc(N3CCNCC3)ccc2O)cn(C2CCCNC2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 12/20 0.47
CDK2 P24941 12/20 0.47
IKBKB O14920 1/20 0.38
CHUK O15111 1/20 0.38
CDK4 P11802 4/20 0.36
CCND1 P24385 4/20 0.36
FGFR1 P11362 2/20 0.36
FGFR2 P21802 2/20 0.36
FGFR4 P22455 2/20 0.36
FGFR3 P22607 2/20 0.36
CCNA2 P20248 1/20 0.36
CCND2 P30279 2/20 0.36
CCND3 P30281 2/20 0.36
SMARCA2 P51531 1/20 0.36
SMARCA4 P51532 1/20 0.36
PBRM1 Q86U86 1/20 0.36
PDE7A Q13946 2/20 0.35
PDE4D Q08499 1/20 0.35
PDE7B Q9NP56 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163727 0.95 CDK1 (0.47) CDK1CDK2IKBKBCHUK
SCHEMBL5166259 0.95 CDK1 (0.45) CDK1CDK2IKBKBCHUKSMARCA2
SCHEMBL5166861 0.94 CDK1 (0.47) CDK1CDK2IKBKBCHUK
SCHEMBL5163995 0.89 CDK1 (0.41) CDK1CDK2IKBKBCHUK
SCHEMBL5166776 0.89 CDK1 (0.43) CDK1CDK2IKBKBCHUK
SCHEMBL5164232 0.87 CDK1 (0.42) CDK1CDK2IKBKBCHUK
SCHEMBL5167086 0.86 CDK1 (0.41) CDK1CDK2IKBKBCHUK
SCHEMBL5167012 0.86 IKBKB (0.45) CDK1CDK2IKBKBCHUKCCNA2
SCHEMBL5164982 0.85 IKBKB (0.40) CDK1CDK2IKBKBCHUK
SCHEMBL5165118 0.85 IKBKB (0.40) CDK1CDK2IKBKBCHUKCCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 US claimed
EP-1678164-B1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORP (US) 2007-04-11 EP claimed
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 US disclosed
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 US disclosed
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 US disclosed
EP-1678164-B1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORP (US) 2007-04-11 EP disclosed
EP-1678164-B1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORP (US) 2007-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation CNKSR1, IL1RN, CHUK CDK1 242/4885CDK2 159/4885IKBKB 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.